pharmaand GmbH and Tolmar, Inc. announced an exclusive agreement for Tolmar to promote Rubraca (rucaparib) in the US for the treatment of metastatic castration-resistant prostate cancer.
[pharmaand GmbH (PR Newswire)]
Home Newsletters The Pharma& Group Enters Into an Exclusive Promotional Agreement With Tolmar, Inc....
